Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Clearmind Medicine Collaborates with Johns Hopkins University for Clinical Research

Thursday, September 07, 2023

Clearmind Medicine has entered into a clinical trial agreement with Johns Hopkins University School of Medicine to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100, known as CM-CMND-001. 

This clinical trial is designed as a multinational, multi-centre study and aims to assess the tolerability, safety, and pharmacokinetics of CMND-100 in both healthy volunteers and individuals with alcohol use disorder (AUD).

This clinical trial represents an important step in exploring the potential of psychedelic drugs like CMND-100 to address neuropsychiatric conditions such as AUD and contribute valuable insights into their therapeutic use.

The primary objective of the CM-CMND-001 clinical trial is to determine the tolerable dosage of CMND-100 and to characterise its safety and pharmacokinetics/pharmacodynamics (PK/PD) in subjects receiving single and repeated doses.

Additionally, the secondary objective of the trial is to assess the effectiveness of CMND-100 in reducing drinking patterns and cravings among individuals with moderate-to-severe AUD. To achieve this, oral capsules of CMND-100 will be administered once daily for ten consecutive days. During the course of the clinical trial, patients will report their drinking patterns and cravings for alcohol, as well as their cravings for cigarettes if applicable.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024